Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide. Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.
Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension. Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).
Istituto Auxologico Italiano., Milan, Italy
25 centers in Germany, Ludwigshafen, Germany
Cedars-Sinai Medical Center, Los Angeles, California, United States
Lucile Packard Children's Hospital, Palo Alto, California, United States
Rady Children's Hospital / UCSD, San Diego, California, United States
Nephrology Department, Sao Paulo University Medical School, Sao Paulo, Brazil
Medical University of Graz, Graz, Austria
Indiana University Hospital GCRC, Indianapolis, Indiana, United States
The University of Texas Southwestern Medical Center, Dallas, Texas, United States
Service de Néphrologie, Hôpital Civil, Hôpitaux Universitaires, Strasbourg, France
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.